Results 11 to 20 of about 142,613 (283)

Significance of Diagnosing Parasitic Infestation in Evaluation of Unexplained Eosinophilia [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2015
Background: The evaluation of unexplained eosinophilia in an asymptomatic individual has always been a diagnostic challenge and requires understanding about a wide range of probable causative agents. Helminthic infestation and schistosomiasis are the
Vinay Khanna   +3 more
doaj   +1 more source

Eosinophilia [PDF]

open access: yesPrimary Care: Clinics in Office Practice, 2016
Eosinophilia is defined as elevation of eosinophils in the bloodstream (450-550 cell/μL). There are many reasons for eosinophilia to exist, including parasitic disease, allergic disease, autoimmune, connective tissue disease, rheumatologic disease, primary eosinophilia such as hypereosinophilic syndrome, and as part of a malignant state.
Anna, Kovalszki, Peter F, Weller
openaire   +2 more sources

Electrochemical detection of Toxocara canis excretory-secretory antigens in children from rural communities in Esmeraldas Province, Ecuador: association between active infection and high eosinophilia. [PDF]

open access: yes, 2020
BACKGROUND: The diagnosis of active Toxocara canis infections in humans is challenging. Larval stages of T. canis do not replicate in human tissues and disease may result from infection with a single T. canis larva.
Chico, M   +9 more
core   +3 more sources

Secondary Eosinophilia A risk factor for prolonged hospitalization in severe COVID-19: A case control study

open access: yesClinical Infection in Practice, 2023
Background: Previous research has shown the potential benefit of eosinophilia in respiratory viral infections, which could suggest a milder clinical course and outcome for those with COVID-19 infection.
Mark Reed   +2 more
doaj   +1 more source

Remission of Kimura disease with carotid hypervascularization after cyclosporine treatment [PDF]

open access: yes, 2020
No abstract ...
Bartolazzi, Armando   +7 more
core   +2 more sources

Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions [PDF]

open access: yes, 2018
Eosinophilic gastrointestinal disorders are a set of conditions with a wide range of clinical manifestations and treatment modalities. The disorders are suspected to result from an abnormal inflammatory response to allergen(s), and individuals may ...
Gupta, Sandeep K., Naramore, Sara
core   +1 more source

Tissue eosinophilia and eosinophil degranulation in Riedel's invasive fibrous thyroiditis. [PDF]

open access: yes, 1996
The etiology of Riedel's invasive fibrous thyroiditis (IFT) has remained obscure. This rare disorder has been confused in the past with the more common fibrous variant of Hashimoto's disease.
Bahn, R. S.   +4 more
core   +1 more source

Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.

open access: yesAmerican Journal of Clinical Pathology, 2020
OBJECTIVES To report the findings of the 2019 Society for Hematopathology/European Association for Haematopathology Workshop within the categories of reactive eosinophilia, hypereosinophilic syndrome (HES), germline disorders with eosinophilia (GDE), and
K. Kelemen   +12 more
semanticscholar   +1 more source

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System

open access: yesInternational Journal of Molecular Sciences, 2017
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe multiorgan hypersensitivity reaction mostly caused by a limited number of eliciting drugs in patients with a genetic predisposition.
Yung-Tsu Cho, Che-Wen Yang, C. Chu
semanticscholar   +1 more source

Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis

open access: yesJEADV Clinical Practice, 2023
Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase‐1 inhibitor and dupilumab, an anti–interleukin‐4 receptor‐α antibody, are approved for moderate‐to‐severe AD.
Delphine Staumont‐Sallé   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy